NCT00057616
Completed
Phase 3
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2, or IFN Based Therapy
DrugsCC-5013
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Melanoma
- Sponsor
- Celgene
- Enrollment
- 274
- Locations
- 49
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects are treated in repeating 4 week cycles.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (49)
Loading locations...
Similar Trials
Completed
Phase 2
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant MelanomaMelanomaNeoplasm MetastasisNCT00055562Celgene Corporation274
Completed
Phase 3
Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter PolymorphismsAlcohol Use DisorderNCT04101227Adial Pharmaceuticals302
Completed
Phase 2
Jinhua Qinggan Granules in the Treatment of COVID-19COVID-19NCT04723524University of Karachi402
Completed
Phase 3
An Study of Efficacy and Safety of ClevudineChronic Hepatitis BNCT01192854Eisai Co., Ltd.288
Completed
Phase 2
Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster HeadachesCluster HeadacheNCT04066023Zosano Pharma Corporation42